EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis

Enrico Costa iD, Joseph S Ross iD, Aaron S Kesselheim iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70349 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Enrico Costa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Italian Medicines Agency (AIFA), Rome, Italy. Hauptthemen laut MEDLINE: Orphan Drug Production, Drug Approval, United States Food and Drug Administration, Rare Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rare disease drugs represent a significant portion of new drug approvals, but the United States and European Union (EU) have differing approaches to Orphan Drug designations, impacting application fees and market exclusivity. This cross‐sectional study analyzed the first rare disease drug approvals in the United States and EU from 2011 to 2020 using data from the Food and Drug Administration (FDA) and European Medicines Agency (EMA) databases, describing similarities and differences in how both regions grant Orphan Drug designations. Out of 344 rare disease drug approvals, 336 (97.7%) were licensed by the FDA with Orphan Drug designations, 139 (40.4%) by the EMA with Orphan Drug designations; 131 (38.1%) were licensed with Orphan Drug designations by both the FDA and EMA, while 103 (29.9%) were approved in the EU without this designation. Additionally, 110 (32.0%) had approval from one agency only, with 102 (29.7%) by the FDA and 8 (2.3%) by the EMA. Both agencies were most consistent in granting Orphan Drug designations for advanced therapies (75.0%) and genetic diseases (55.4%). EMA approvals were lacking for tropical diseases (12.7%), while EU designations were often absent for diseases not considered distinct entities, such as subsets of cancers or pediatric indications of prevalent diseases. These findings reflect the differing regulatory frameworks and practices between the United States and the EU. Policymakers seeking to improve rare disease drug approval could prioritize incentives for the development of treatments for truly rare diseases as opposed to subsets of more common conditions for which incentives have already been established or create pathways that tackle scientific and societal challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orphan Drug ProductionDrug ApprovalUnited States Food and Drug AdministrationRare DiseasesUnited StatesEuropean UnionHumansCross-Sectional StudiesDatabases, Factual

Autor:innen und Institutionen

  • Italian Medicines Agency (AIFA), Rome, Italy.
  • Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Enrico Costa, Joseph S Ross, Aaron S Kesselheim

Zitieren

APA

Costa, E., Ross, J. S., & Kesselheim, A. S. (2026). Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70349

Vancouver

Costa E, Ross JS, Kesselheim AS. Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70349

BibTeX
@article{Costa2026,
  author = {Costa, Enrico and Ross, Joseph S and Kesselheim, Aaron S},
  title = {Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70349}
}
Kostenlos starten →